目的:测定肽类药物曲普瑞林、促黄体素释放激素类似物的分子量及其一级结构。方法:应用电喷雾质谱法(ESI MS)及源内碰撞诱导解离技术对肽类药物曲普瑞林及促黄体素释放激素类似物进行测定,根据其典型碎片离子确证其氨基酸序列及分子量...目的:测定肽类药物曲普瑞林、促黄体素释放激素类似物的分子量及其一级结构。方法:应用电喷雾质谱法(ESI MS)及源内碰撞诱导解离技术对肽类药物曲普瑞林及促黄体素释放激素类似物进行测定,根据其典型碎片离子确证其氨基酸序列及分子量。结果:肽类化合物在正离子模式下可得到较好的质谱信息,2种寡肽均测得其准分子离子峰(M+H)^+及(M+Na)^+信号,分子量分别与理论值一致。利用电喷雾碰撞诱导解离方法,得到一系列典型的 y 及 b 系列碎片离子,从而确证了2种寡肽的一级结构。结论:本研究为测定寡肽的分子量和一级结构提供了一个简便、快速、准确的方法。展开更多
The introduction of new cytotoxic substances as well as agents that target vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) signaling has improved clinical outcome of patients with...The introduction of new cytotoxic substances as well as agents that target vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) signaling has improved clinical outcome of patients with metastatic colorectal cancer (mCRC). In this review we summarize the most relevant clinical data on VEGF and EGFR targeting regimens in mCRC. The effects of available treatment strategies for mCRC are often temporary, with resistance and disease progression developing in most patients. Thus, new treatment strategies are urgently needed. Some GI peptides including gastrin and gastrin releasing peptide, certain growth factors such as insulin-like growth factor-I and II and neuropeptides such as growth hormone releasing hormone (GHRH) are implicated in the growth of CRC. Experimental investigations in CRC with antagonistic analogs of bombesin/gastrin-releasing peptide, GHRH, and with cytotoxic peptides that can be targeted to peptide receptors on tumors, are summarized in the second part of the review.展开更多
文摘目的:测定肽类药物曲普瑞林、促黄体素释放激素类似物的分子量及其一级结构。方法:应用电喷雾质谱法(ESI MS)及源内碰撞诱导解离技术对肽类药物曲普瑞林及促黄体素释放激素类似物进行测定,根据其典型碎片离子确证其氨基酸序列及分子量。结果:肽类化合物在正离子模式下可得到较好的质谱信息,2种寡肽均测得其准分子离子峰(M+H)^+及(M+Na)^+信号,分子量分别与理论值一致。利用电喷雾碰撞诱导解离方法,得到一系列典型的 y 及 b 系列碎片离子,从而确证了2种寡肽的一级结构。结论:本研究为测定寡肽的分子量和一级结构提供了一个简便、快速、准确的方法。
文摘The introduction of new cytotoxic substances as well as agents that target vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) signaling has improved clinical outcome of patients with metastatic colorectal cancer (mCRC). In this review we summarize the most relevant clinical data on VEGF and EGFR targeting regimens in mCRC. The effects of available treatment strategies for mCRC are often temporary, with resistance and disease progression developing in most patients. Thus, new treatment strategies are urgently needed. Some GI peptides including gastrin and gastrin releasing peptide, certain growth factors such as insulin-like growth factor-I and II and neuropeptides such as growth hormone releasing hormone (GHRH) are implicated in the growth of CRC. Experimental investigations in CRC with antagonistic analogs of bombesin/gastrin-releasing peptide, GHRH, and with cytotoxic peptides that can be targeted to peptide receptors on tumors, are summarized in the second part of the review.
